Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the ...
Drug manufacturing giant GSK is subverting its pledge to lower the price of its brand-name inhaler products, a key Democratic ...
When PBMs refuse to cover the cheaper generic, patients are left on the hook for the full cost. Insurers and employers hire ...
GSK pledged March 20 to cap out-of-pocket costs for its ... companies for setting high inhaler prices that they say are unreasonable; for instance, AstraZeneca in January charged about $650 ...
When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the ...
Toward the end of March, GSK followed in the footsteps of Boehringer Ingelheim and AstraZeneca when it pledged to cap out-of-pocket costs for its inhalers at $35 per month by Jan. 1, 2025. Aside from ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
Sanders and other lawmakers in January criticized four makers of inhalers sold in the U.S. — AstraZeneca, Boehringer ... In March, three of the four companies decided to cap inhaler costs at $35 each.
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and ...
In response to the FTC’s November challenges, Kaleo, Impax Labs, GSK delisted patents, and AstraZeneca, Boehringer Ingelheim, ...
Some doctors are promoting propellant-free inhalers over puff inhalers that emit greenhouse gases. Climate change can ...